GreenLight Biosciences is a privately held biotechnology company based in Medford, Massachusetts that was founded in 2009 by Andrey J. Zarur and Marta Ortega-Valle. The company focuses on sustainable production of chemicals and fuels using its patented cell-free bioprocessing technology platform. It develops RNA products for plant and life science applications, and collaborates with companies from various industries for vaccine development, pandemic preparation, crop management, and plant protection.
In October 2018, GreenLight entered into a research collaboration with AgroSpheres to study the delivery of GreenLight's double stranded RNA (dsRNA) using AgroSphere's proprietary bioparticle platform.
On July 10, 2009 Greenlight Biosciences completed their series A funding round with $4.29 million in funding from undisclosed investors.
On December 20, 2013 Greenlight Biosciences completed their series B funding round with $10.5 million in funding from undisclosed investors.
On June 15, 2015 Greenlight Biosciences completed their series C funding round with $20 million in funding from undisclosed investors.
On September 13, 2017 Greenlight Biosciences completed their series D funding round with $18 million in funding from Fall Line Capital (lead investor), S2G Ventures, Lewis and Clark Ventures, Macro Capital Investments, Kodiak Venture Partners, MLSCF, Syngenta Ventures, and other previous investors. The company is planning on using their series D funding to speed up the development of field testing several of the companies dsRNA molecules for targeting insects and viral pests in high-value crop products.
On January 8, 2019 Greenlight Biosciences completed a venture capital funding round with $50 million in funding from S2G Ventures (lead investor), Baird Capital (lead investor), Blue I/O (lead investor), Continental Grain Company, Tao Capital Partners, Alexandria Venture Investments, and several previous investors. The company plans on using the funding to expand their research and development platform for bio-control products, human and animal vaccines, and therapeutics.
GreenLight Biosciences raises a $18,000,000 series D round from Fall Line Capital, S2G Ventures, Lewis & Clark Ventures and Macro Capital Investments.
GreenLight Biosciences raises a $7,000,000 series A round from Khosla Ventures.
Andrey J. Zarur
Co-Founder, President, & CEO
Director of Platform R&D
Co-Founder, Senior VP, Corporate Development
Manager of Analytical Chemistry
AgroSpheres enters research collaboration with GreenLight Biosciences - Virginia Bio
GreenLight Biosciences aims at a revolution in the chemical industry
GreenLight Biosciences Announces $50 Million Funding Round
GreenLight Biosciences, Inc.